Juji Takeuchi, MD

Affiliations: 
Neurosurgery Kyoto University, Kyōto-shi, Kyōto-fu, Japan 
Google:
"Juji Takeuchi"
Bio:

http://onlinelibrary.wiley.com/doi/10.1111/j.1528-1157.1998.tb01926.x/abstract

http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6TCB-4C717BB-NW&_user=10&_coverDate=02/28/1981&_rdoc=1&_fmt=high&_orig=search&_origin=search&_

Mean distance: 19.07 (cluster 24)
 
SNBCP
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Takeuchi JS, Ren F, Yoshikawa R, et al. (2015) Coevolutionary dynamics between tribe Cercopithecini tetherins and their lentiviruses. Scientific Reports. 5: 16021
Iwami S, Takeuchi JS, Nakaoka S, et al. (2015) Cell-to-cell infection by HIV contributes over half of virus infection. Elife. 4
Sato K, Kobayashi T, Misawa N, et al. (2015) Experimental evaluation of the zoonotic infection potency of simian retrovirus type 4 using humanized mouse model. Scientific Reports. 5: 14040
Itadani S, Yashiro K, Aratani Y, et al. (2015) Discovery of Gemilukast (ONO-6950), a Dual CysLT1 and CysLT2 Antagonist As a Therapeutic Agent for Asthma. Journal of Medicinal Chemistry. 58: 6093-113
Iwami S, Sato K, Morita S, et al. (2015) Pandemic HIV-1 Vpu overcomes intrinsic herd immunity mediated by tetherin. Scientific Reports. 5: 12256
Itadani S, Takahashi S, Ima M, et al. (2015) Discovery of a potent, orally available dual CysLT₁ and CysLT₂ antagonist with dicarboxylic acid. Bioorganic & Medicinal Chemistry. 23: 2079-97
Yoshikawa R, Takeuchi JS, Yamada E, et al. (2015) Vif determines the requirement for CBF-β in APOBEC3 degradation. The Journal of General Virology. 96: 887-92
Itadani S, Yashiro K, Aratani Y, et al. (2015) Discovery of Gemilukast (ONO-6950), a Dual CysLT1 and CysLT2 Antagonist As a Therapeutic Agent for Asthma Journal of Medicinal Chemistry. 58: 6093-6113
Yamamoto K, Koh H, Shimada H, et al. (2014) Cerebral infarction in the left hemisphere compared with the right hemisphere increases the risk of aspiration pneumonia. Osaka City Medical Journal. 60: 81-6
Inokuchi K, Kumagai T, Matsuki E, et al. (2014) Efficacy of molecular response at 1 or 3 months after the initiation of dasatinib treatment can predict an improved response to dasatinib in imatinib-resistant or imatinib-intolerant Japanese patients with chronic myelogenous leukemia during the chronic phase. Journal of Clinical and Experimental Hematopathology : Jceh. 54: 197-204
See more...